Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | HTR5A | P47898 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28459559 | 0.93 | MEN1 (0.45) | HSD17B10MEN1KMT2ABRD3KDM4E | |
| SCHEMBL28459535 | 0.93 | MEN1 (0.45) | HSD17B10MEN1KMT2ABRD3KDM4E | |
| SCHEMBL28465952 | 0.93 | MEN1 (0.45) | HSD17B10MEN1KMT2ABRD3KDM4E | |
| SCHEMBL1919190 | 0.89 | HTR2A (0.46) | HSD17B10MEN1KMT2ABRD3KDM4E | |
| SCHEMBL296017 | 0.76 | HSD17B10 (0.48) | HSD17B10MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL15101404 | 0.76 | KDM4E (0.54) | HSD17B10MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL224482 | 0.75 | MEN1 (0.47) | HSD17B10MEN1KMT2ABRD3KDM4E | |
| SCHEMBL2307927 | 0.74 | HTR2A (0.43) | HSD17B10MEN1KMT2ABRD3KDM4E | |
| SCHEMBL481360 | 0.71 | KDM4E (0.68) | HSD17B10MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29936982 | 0.71 | KDM4E (0.68) | HSD17B10MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11965102-B2 | Photochromic annelated naphthopyrane systems with special substituents, for attaining rapid lightening speeds | RODENSTOCK GMBH (DE) | 2024-04-23 | — | — | US | claimed |
| CN-112424180-B | Photochromic fused naphthopyran systems with specific substituents for obtaining high lightening speeds | 罗登斯托克有限责任公司 | 2023-12-08 | — | — | CN | claimed |
| EP-4240797-A1 | COMBINATION OF SPECIFIC ANNELLATED NAPHTHOPYRANE ISOMERS | Rodenstock GmbH (DE) | 2023-09-13 | — | — | EP | claimed |
| WO-2023135127-A1 | COMBINATION OF SPECIFIC ANNELLATED NAPHTHOPYRANE ISOMERS | RODENSTOCK GMBH (DE) | 2023-07-20 | — | — | WO | claimed |
| CN-115960032-A | Aryloxy propanol amine beta-adrenaline receptor ligand with beta-arrestin biased agonistic activity and application thereof | 复旦大学 | 2023-04-14 | — | — | CN | claimed |
| EP-3925989-A1 | MOLECULAR WEIGHT CONTROL OF POLYOLEFINS USING HALOGENATED BIS-PHENYLPHENOXY CATALYSTS | Dow Global Technologies LLC (US) | 2021-12-22 | — | — | EP | claimed |
| EP-3807258-B1 | PHOTOCHROMIC ANNELATED NAPHTHOPYRANE SYSTEMS WITH SPECIAL SUBSTITUENTS, FOR ATTAINING RAPID LIGHTENING SPEEDS | RODENSTOCK GMBH (DE) | 2021-10-20 | — | — | EP | claimed |
| US-20210253865-A1 | PHOTOCHROMIC ANNELATED NAPHTHOPYRANE SYSTEMS WITH SPECIAL SUBSTITUENTS, FOR ATTAINING RAPID LIGHTENING SPEEDS | RODENSTOCK GMBH (DE) | 2021-08-19 | — | — | US | claimed |
| CN-113201084-A | Molecular weight control of polyolefins using halogenated bisphenylphenoxy catalysts | 陶氏环球技术有限责任公司 | 2021-08-03 | — | — | CN | claimed |
| EP-3386511-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2021-05-12 | — | — | EP | claimed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | claimed |
| WO-2006128129-A2 | METHOD FOR TREATING CANCER | SYNTA PHARMACEUTICALS CORP. (US) | 2006-11-30 | — | — | WO | claimed |
| WO-2006128172-A2 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060122156-A1 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | claimed |
| WO-2006053109-A1 | HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | claimed |
| EP-1009740-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | Merck & Co., Inc. (US) | 2000-06-21 | — | — | EP | claimed |
| US-5935968-A | ADMINISTERING ANDROSTENE DERIVATIVE 5-ALPHA REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1999-08-10 | — | — | US | claimed |
| WO-1998041509-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | MERCK & CO., INC. (US) | 1998-09-24 | — | — | WO | claimed |
| EP-0340010-B1 | Heterocyclic nitromethane derivatives | ICI PLC (GB) | 1994-08-24 | — | — | EP | claimed |
| EP-0340010-A2 | Heterocyclic nitromethane derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-11-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122156-A1 | Heteroaryl compounds | IL2, CCL11, IL4 | HSD17B10 497/4885MEN1 3198/4885KMT2A 3739/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | HSD17B10 3453/4885MEN1 3751/4885KMT2A 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.